Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,459 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E; NETTER-1 study group. Strosberg J, et al. Among authors: he b. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2372-2382. doi: 10.1007/s00259-020-04709-x. Epub 2020 Mar 2. Eur J Nucl Med Mol Imaging. 2020. PMID: 32123969 Free PMC article. Clinical Trial.
Efficacy and safety of 177Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study.
Clement D, Navalkissoor S, Srirajaskanthan R, Courbon F, Dierickx L, Eccles A, Lewington V, Mitjavila M, Percovich JC, Lequoy B, He B, Folitar I, Ramage J. Clement D, et al. Among authors: he b. Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3529-3537. doi: 10.1007/s00259-022-05771-3. Epub 2022 Apr 7. Eur J Nucl Med Mol Imaging. 2022. PMID: 35389069 Free PMC article.
Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
Calais J, Czernin J, Thin P, Gartmann J, Nguyen K, Armstrong WR, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Dahlbom M, He B, Esfandiari R, Ranganathan D, Herrmann K, Eiber M, Fendler WP, Delpassand E. Calais J, et al. Among authors: he b. J Nucl Med. 2021 Oct;62(10):1447-1456. doi: 10.2967/jnumed.121.262543. Epub 2021 Jul 16. J Nucl Med. 2021. PMID: 34272322 Free PMC article.
7,459 results